Association of Carotid Plaque Lp-PLA2 with Macrophages and Chlamydia pneumoniae infection among Patients at Risk for Stroke

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Atik, Berna ^a   Johnston, S Claiborne ^b   Dean, Deborah ^a,b,c,d  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California at Berkeley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; HOMOCYSTEINE;

AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; GENETIC DISORDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; OBESITY; RISK FACTOR; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; CAROTID ARTERIES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RISK FACTORS; STROKE;

CHLAMYDOPHILA PNEUMONIAE;

EID: 77956221171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011026     Document Type: Article

References (49)

1. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, et al. (2000) Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151: 478-487.
2. Mohler ER, 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, et al. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51: 1632-1641.
3. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, et al. (1999) Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 261: 511-514.
4. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, et al. (1991) Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem 266: 16667-16673.
5. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, et al. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 (Pt 2): 479-487.
6. Koenig W, Twardella D, Brenner H, Rothenbacher D (2006) Lipoproteinassociated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26: 1586-1593.
7. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, et al. (2004) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109: 837-842.
8. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, et al. (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343: 1148-1155.
9. Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, et al. (1999) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19: 2909-2917.
10. Saikku P (1992) The epidemiology and significance of Chlamydia pneumoniae. J Infect 25 Suppl 1: 27-34.
11. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, et al. (1995) Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 92: 6911-6914.
12. Muhlestein JB (1999) Animal models of chlamydia and atherosclerosis. Am Heart J 138: S514-515.
13. Ramirez JA (1996) Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 125: 979-982.
14. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P (1997) Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 65: 4832-4835.
15. Sessa R, Nicoletti M, Di Pietro M, Schiavoni G, Santino I, et al. (2009) Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int J Immunopathol Pharmacol 22: 9-14.
16. Grayston JT (2000) Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181 Suppl 3: S402-410.
17. Chiu B, Viira E, Tucker W, Fong IW (1997) Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 96: 2144-2148.
18. Johnston SC, Zhang H, Messina LM, Lawton MT, Dean D (2005) Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum. Arterioscler Thromb Vasc Biol 25: 2648-2653.
19. Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, et al. (2001) Creactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke 32: 2748-2752.
20. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q (2000) Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 102: 833-839.
21. LaBiche R, Koziol D, Quinn TC, Gaydos C, Azhar S, et al. (2001) Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque. Stroke 32: 855-860.
22. Apfalter P, Loidl M, Nadrchal R, Makristathis A, Rotter M, et al. (2000) Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur J Clin Microbiol Infect Dis 19: 305-308.
23. Ramirez JA, Ahkee S, Ganzel B, Ogend L, Gaydos CA, et al. (1996) Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 125: 979-982.
24. Hauer AD, de Vos P, Peterse N, Ten Cate H, van Berkel TJ, et al. (2006) Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr2/2 mice. Cardiovasc Res 69: 280-288.
25. de Kruif MD, van Gorp EC, Keller TT, Ossewaarde JM, ten Cate H (2005) Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65: 317-327.
26. Blessing E, Campbell LA, Rosenfeld ME, Chesebro B, Kuo CC (2005) A 6 week course of azithromycin treatment has no beneficial effect on atheroscleroticlesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae. J Antimicrob Chemother 55: 1037-1040.
27. Bunk S, Susnea I, Rupp J, Summersgill JT, Maass M, et al. (2008) Immunoproteomic identification and serological responses to novel Chlamydia pneumoniae antigens that are associated with persistent C. pneumoniae infections. J Immunol 180: 5490-5498.
28. Gieffers J, Solbach W, Maass M (2001) In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther 15: 259-262
29. Oldgren J, James SK, Siegbahn A, Wallentin L (2007) Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28: 699-704.
30. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, et al. (2009) Lipoproteinassociated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 30: 107-115.
31. 2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmo, Sweden. Atherosclerosis 200: 191-198.
32. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, et al. (2006) Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 26: 631-636.
33. Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, et al. (2005) Lack of association between carotid intima-media thickness and PAFacetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 56: 451-458.
34. Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, et al. (2007) Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. J Viral Hepat 14: 22-28.
35. Vadas P, Taylor TE, Chimsuku L, Goldring D, Stefanski E, et al. (1993) Increased serum phospholipase A2 activity in Malawian children with falciparum malaria. Am J Trop Med Hyg 49: 455-459.
36. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, et al. (2001) Highdensity lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103: 2283-2288.
37. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, et al. (1999) Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 180: 780-790.
38. Carlquist JF, Muhlestein JB, Anderson JL (2007) Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 7: 511-517.
39. 2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J 20: 1727-1729.
40. Amberger A, Maczek C, Jurgens G, Michaelis D, Schett G, et al. (1997) Coexpression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 2: 94-103.
41. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, et al. (1999) Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99: 3103-3109.
42. Quinn MT, Parthasarathy S, Steinberg D (1988) Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 85: 2805-2809.
43. Kume N, Cybulsky MI, Gimbrone MA, Jr. (1992) Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138-1144.
44. Chang MY, Tsoi C, Wight TN, Chait A (2003) Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. Arterioscler Thromb Vasc Biol 23: 809-815.
45. Rodel J, Woytas M, Groh A, Schmidt KH, Hartmann M, et al. (2000) Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 68: 3635-3641.
46. Högdahl M, Söderlund G, Kihlström E (2008) Expression of chemokines and adhesion molecules in human coronary artery endothelial cells infected with Chlamydia (Chlamydophila) pneumoniae. APMIS 116: 1082-1088.
47. Jitsuiki K, Yamane K, Nakajima M, Nakanishi S, Tasaki N, et al. (2006) Association of Chlamydia pneumoniae infection and carotid intima-media wall thickness in Japanese Americans. Circ J 70: 815-819.
48. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, et al. (2008) Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: The Cardiovascular Health Study. J Am Geriatr Soc 56: 792-799.
49. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C (2009) Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 30: 6-15.